Therapeutic Application of Alpha-1 Antitrypsin in COVID-19
Am J Respir Crit Care Med
.
2021 Jul 15;204(2):224-227.
doi: 10.1164/rccm.202104-0833LE.
Authors
Felix Ritzmann
1
,
Praneeth Chitirala
1
,
Nadine Krüger
2
,
Markus Hoffmann
2
3
,
Wei Zuo
4
,
Frank Lammert
1
5
,
Sigrun Smola
6
,
Naveh Tov
7
,
Noga Alagem
7
,
Philipp M Lepper
1
,
Stefan Pöhlmann
2
3
,
Christoph Beisswenger
1
,
Christian Herr
1
,
Robert Bals
1
;
AAT-in-COVID-19 Study Group
Collaborators
AAT-in-COVID-19 Study Group
:
Yiwen Yao
,
Nastasja Seiwert
,
Guy Danziger
Affiliations
1
Saarland University Homburg, Germany.
2
German Primate Center-Leibniz Institute for Primate Research Göttingen, Germany.
3
University of Göttingen Göttingen, Germany.
4
Tongji University Shanghai, China.
5
Hannover Medical School Hannover, Germany.
6
Saarland University Medical Center Homburg, Germany.
7
Kamada Ltd. Rehovot, Israel.
PMID:
33961754
PMCID:
PMC8650782
DOI:
10.1164/rccm.202104-0833LE
No abstract available
Publication types
Letter
MeSH terms
COVID-19 / epidemiology
COVID-19 Drug Treatment*
Humans
Pandemics*
SARS-CoV-2*
Trypsin Inhibitors / pharmacology
alpha 1-Antitrypsin / therapeutic use*
Substances
Trypsin Inhibitors
alpha 1-Antitrypsin